Successful Completion and Interim Results of Ph 1 Study of HC-5404 in Solid Tumors announced
“We are excited to announce the successful completion of our Phase 1 monotherapy study of HC-5404 along with the two publications in Clinical Cancer Research,” said Jonathan Lanfear, President and CEO. “We are encouraged by the safety profile, dose-dependent exposure, and pathway engagement, as well as the preliminary signals of efficacy observed in our Phase 1 trial. This provides a forward path for Ph1b/Ph2 studies in multiple indications/combinations as outlined in our publications in Clinical Cancer Research. Our publications also highlight some of the promise of HC-5404, including the potential to resensitize tumors to TKI therapy, increase the overall response rate in combination with TKI as demonstrated in PDX models, as well as inhibiting metastasis by blocking survival of disseminated dormant cancer cells.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib